Published in J Virol on August 01, 2000
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J (2003) 4.19
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A (2001) 2.86
Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol (2002) 2.49
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog (2007) 2.14
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol (2010) 2.12
Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 2.06
Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol (2005) 2.05
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology (2008) 1.89
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol (2002) 1.81
Antigenically distinct conformations of CXCR4. J Virol (2001) 1.74
Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol (2004) 1.72
Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol (2005) 1.70
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol (2005) 1.65
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther (2005) 1.53
Pannexin1 hemichannels are critical for HIV infection of human primary CD4+ T lymphocytes. J Leukoc Biol (2013) 1.51
Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology (2007) 1.46
A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci U S A (2000) 1.45
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol (2005) 1.42
Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med (2007) 1.41
Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. J Virol (2002) 1.37
Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor. J Virol (2005) 1.36
Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell (2005) 1.32
Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol (2002) 1.29
Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med (2002) 1.28
Localization of CD4 and CCR5 in living cells. J Virol (2003) 1.28
Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc Natl Acad Sci U S A (2000) 1.24
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol (2003) 1.19
Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events. J Virol (2004) 1.17
Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1. J Virol (2006) 1.15
Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog (2009) 1.14
Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol (2005) 1.13
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A (2008) 1.09
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
Oligomeric beta-structure of the membrane-bound HIV-1 fusion peptide formed from soluble monomers. Biophys J (2004) 1.04
Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion. J Virol (2003) 1.03
The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virol J (2006) 1.01
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J Mol Biol (2007) 0.99
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions. J Virol (2002) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology (2012) 0.95
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol (2003) 0.95
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol (2011) 0.94
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol (2007) 0.93
Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS Pathog (2015) 0.92
The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages. Virus Res (2006) 0.91
CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain. J Virol (2001) 0.91
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One (2014) 0.88
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology (2011) 0.86
Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. PLoS One (2011) 0.86
Linkage of reduced receptor affinity and superinfection to pathogenesis of TR1.3 murine leukemia virus. J Virol (2006) 0.86
Gelsolin activity controls efficient early HIV-1 infection. Retrovirology (2013) 0.86
Recruitment of HIV-1 envelope occurs subsequent to lipid mixing: a fluorescence microscopic evidence. Retrovirology (2009) 0.86
Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentration. J Virol (2002) 0.86
Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol (2008) 0.85
Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses. Biophys J (2009) 0.83
CCR5Delta32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivo. J Virol (2007) 0.83
Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail. Virol J (2008) 0.83
Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol Chem (2014) 0.82
The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology (2007) 0.82
Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. Virology (2006) 0.80
Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection. J Acquir Immune Defic Syndr (2011) 0.80
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms. J Virol (2014) 0.79
G541R within the 4070A TM protein regulates fusion in murine leukemia viruses. J Virol (2003) 0.79
Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. PLoS Comput Biol (2009) 0.79
Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity. PLoS Pathog (2013) 0.78
Double-edged genetic swords and immunity: lesson from CCR5 and beyond. J Infect Dis (2010) 0.78
Stochastic entry of enveloped viruses: fusion versus endocytosis. Biophys J (2007) 0.78
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention. AIDS (2011) 0.78
Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency. Biophys J (2011) 0.77
Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. Virology (2015) 0.77
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathog (2016) 0.77
Viral infection: Moving through complex and dynamic cell-membrane structures. Commun Integr Biol (2011) 0.76
P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. J Virol (2015) 0.76
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76
CCR5 promoter haplotype transcription complex characterization. J Health Care Poor Underserved (2011) 0.75
Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1. AIDS Res Hum Retroviruses (2015) 0.75
Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS (2016) 0.75
Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections. J Math Biol (2014) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
Physics of chemoreception. Biophys J (1977) 15.69
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
HIV entry and its inhibition. Cell (1998) 9.42
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell (1999) 4.97
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A (1999) 4.61
Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science (1996) 4.39
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (1996) 3.84
Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers. J Cell Biol (1996) 3.77
The adsorption of coliphage lambda to its host: effect of variations in the surface density of receptor and in phage-receptor affinity. J Mol Biol (1976) 3.75
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol (1998) 3.11
CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04
HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J (1997) 2.86
Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events. J Cell Biol (1996) 2.79
Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem (1998) 2.57
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
Chemokine receptors: keys to AIDS pathogenesis? Cell (1998) 2.15
Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci U S A (1988) 2.02
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem (1997) 1.99
Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci U S A (1999) 1.88
CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol (1998) 1.85
Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol (1998) 1.83
Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1. J Virol (1995) 1.81
Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J Virol (1997) 1.77
Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol (1997) 1.75
Morphogenesis and morphology of HIV. Structure-function relations. Arch Virol (1989) 1.63
Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol (1999) 1.51
Minimal aggregate size and minimal fusion unit for the first fusion pore of influenza hemagglutinin-mediated membrane fusion. Biophys J (2000) 1.40
Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol (1998) 1.36
Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem (1999) 1.34
The organization of the envelope projections on the surface of HIV. Arch Virol (1988) 1.30
A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem (1999) 1.28
Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sci U S A (1999) 1.27
Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 1.05
CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. J Virol (1999) 1.04
Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process. J Virol (1996) 1.02
Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1. J Biol Chem (1999) 1.01
Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates. AIDS Res Hum Retroviruses (1999) 0.91
CCR5 HIV-1 coreceptor activity. Role of cooperativity between residues in N-terminal extracellular and intracellular domains. J Biol Chem (1999) 0.82
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. Proc Natl Acad Sci U S A (1975) 9.15
Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter. Nature (1991) 4.84
Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A (1994) 4.07
Structure-activity relationships of an exotoxin of Pseudomonas aeruginosa. Infect Immun (1977) 3.63
Unexpectedly large size of globin messenger ribonucleic acid. Proc Natl Acad Sci U S A (1971) 3.56
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Evidence for a glycoprotein "signal" involved in transport between subcellular organelles. Two membrane glycoproteins encoded by murine leukemia virus reach the cell surface at different rates. J Biol Chem (1982) 3.24
Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun (1977) 3.17
CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73
Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc Natl Acad Sci U S A (1999) 2.62
Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol (1989) 2.52
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Improved methods for purification and assay of eukaryotic messenger ribonucleic acids and ribosomes. Quantitative analysis of their interaction in a fractionated reticulocyte cell-free system. J Biol Chem (1975) 2.30
Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus. J Virol (1977) 2.26
Isotopic labeling and analysis of phosphoproteins from mammalian ribosomes. Methods Enzymol (1974) 2.19
Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J Virol (1991) 2.05
Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci U S A (1988) 2.02
Glycoprotein encoded by the Friend spleen focus-forming virus. J Virol (1979) 1.89
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol (1991) 1.81
Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J Virol (1990) 1.78
Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J Virol (1997) 1.77
Gene selection in hemoglobin and in antibody-synthesizing cells. Science (1972) 1.76
The membrane glycoprotein of Friend spleen focus-forming virus: evidence that the cell surface component is required for pathogenesis and that it binds to a receptor. J Virol (1987) 1.67
Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int (1996) 1.66
The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J Virol (1991) 1.58
A sodium-dependent neutral-amino-acid transporter mediates infections of feline and baboon endogenous retroviruses and simian type D retroviruses. J Virol (1999) 1.58
Phosphorylation of ribosomal proteins in rabbit reticulocytes. Characterization and regulatory aspects. Biochemistry (1970) 1.56
Polymorphisms of the cell surface receptor control mouse susceptibilities to xenotropic and polytropic leukemia viruses. J Virol (1999) 1.55
Competition between globin messenger ribonucleic acids for a discriminating initiation factor. J Biol Chem (1977) 1.51
A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily. J Virol (1999) 1.48
Loss of leukemogenicity caused by mutations in the membrane glycoprotein structural gene of Friend spleen focus-forming virus. Proc Natl Acad Sci U S A (1983) 1.47
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47
Plasma membrane glycoproteins encoded by cloned Rauscher and Friend spleen focus-forming viruses. J Virol (1980) 1.46
Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J Virol (1997) 1.44
Phosphorylation of ribosomal proteins in rabbit reticulocytes. A cell-free system with ribosomal protein kinase activity. Biochemistry (1971) 1.43
The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible species. J Virol (1995) 1.43
Cell surface receptors for gammaretroviruses. Curr Top Microbiol Immunol (2003) 1.42
Role of the PU.1 transcription factor in controlling differentiation of Friend erythroleukemia cells. Mol Cell Biol (1992) 1.41
Molecular cloning of biologically active Rauscher spleen focus-forming virus and the sequences of its env gene and long terminal repeat. J Virol (1984) 1.38
A murine leukemia virus mutant with a temperature-sensitive defect in membrane glycoprotein synthesis. Cell (1979) 1.34
Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem (1995) 1.34
Synthesis of erythrocyte-specific proteins in cultured friend leukemia cells. Cell (1975) 1.33
Constitutive expression of steel factor gene by human stromal cells. Blood (1993) 1.33
Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene. Proc Natl Acad Sci U S A (1990) 1.33
A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem (1999) 1.28
Effects of ecotropic murine retroviruses on the dual-function cell surface receptor/basic amino acid transporter. J Biol Chem (1992) 1.27
Disulfide bonding controls the processing of retroviral envelope glycoproteins. J Biol Chem (1991) 1.27
Role of a membrane glycoprotein in Friend virus-induced erythroleukemia: studies of mutant and revertant viruses. Virology (1985) 1.25
Genetic and sialylation sources of heterogeneity of the murine leukemia virus membrane envelope glycoproteins gp69/71. J Biol Chem (1979) 1.24
A common site for immortalizing proviral integrations in Friend erythroleukemia: molecular cloning and characterization. J Virol (1989) 1.23
Heterogeneous metabolism and subcellular localization of a potentially leukemogenic membrane glycoprotein encoded by Friend erythroleukemia virus. Isolation of viral and cellular processing mutants. J Biol Chem (1982) 1.22
Potentiation of hemoglobin messenger ribonucleic acid. A step in protein synthesis initiation involving interaction of messenger with 18 S ribosomal ribonucleic acid. J Biol Chem (1975) 1.20
The Ets-related transcription factor PU.1 immortalizes erythroblasts. Mol Cell Biol (1993) 1.20
Highly sensitive immunoadsorption procedure for detection of low-abundance proteins. Anal Biochem (1986) 1.18
Glycosylation and intracellular transport of membrane glycoproteins encoded by murine leukemia viruses. Inhibition by amino acid analogues and by tunicamycin. J Biol Chem (1982) 1.15
Host-range control of a retroviral disease: Friend erythroleukemia. Trends Microbiol (1995) 1.13
Changes in RNA and protein metabolism preceding onset of hemoglobin synthesis in cultured Friend leukemia cells. Dev Biol (1976) 1.12
A tagged helper-free Friend virus causes clonal erythroblast immortality by specific proviral integration in the cellular genome. J Virol (1988) 1.11
The ribosomal subunit--polyribosome cycle in protein synthesis of embryonic skeletal muscle. Biochemistry (1969) 1.08
Relationship of Friend murine leukemia virus production to growth and hemoglobin synthesis in cultured erythroleukemia cells. J Virol (1976) 1.08
Reduced leukemogenicity caused by mutations in the membrane glycoprotein gene of Rauscher spleen focus-forming virus. J Virol (1984) 1.07
Cell surface site for mitogenic interaction of erythropoietin receptors with the membrane glycoprotein encoded by Friend erythroleukemia virus. J Biol Chem (1993) 1.07
Immunoselection of mutants deficient in cell surface glycoproteins encoded by murine erythroleukemia viruses. Proc Natl Acad Sci U S A (1980) 1.05
Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 1.05
Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus. J Virol (2000) 1.04
Roles of helper and defective retroviral genomes in murine erythroleukemia: studies of spleen focus-forming virus in the absence of helper. J Virol (1985) 1.04
Expression of the silent hemoglobin gene in sheep. Studies of the globin messenger ribonucleic acids. J Biol Chem (1972) 1.03
A weakly pathogenic Rauscher spleen focus-forming virus mutant that lacks the carboxyl-terminal membrane anchor of its envelope glycoprotein. J Virol (1985) 1.02
Control of cationic amino acid transport and retroviral receptor functions in a membrane protein family. J Biol Chem (1994) 1.02
Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process. J Virol (1996) 1.02
Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol (2000) 1.02
Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1. J Biol Chem (1999) 1.01
Effect of cyclic adenosine 3':5'-monophosphate on ribosomal protein phosphorylation in reticulocytes. J Biol Chem (1974) 1.01
A comprehensive approach to mapping the interacting surfaces of murine amphotropic and feline subgroup B leukemia viruses with their cell surface receptors. J Virol (2000) 1.01
Mutant cells that abnormally process plasma membrane glycoproteins encoded by murine leukemia virus. Cell (1981) 1.01
The switch from fetal to adult hemoglobin in humans: evidence suggesting a role for gamma-beta gene linkage. Ann N Y Acad Sci (1974) 0.98